Activating mutations in the NOTCH1 pathway are frequent in pediatric T-cell acute lymphoblastic leukemia (T-ALL) but their role in refining risk stratification is unclear. We screened 162 pediatric T-ALL patients treated on the MRC UKALL2003 trial for NOTCH1/FBXW7 gene mutations and related genotype to response to therapy and long-term outcome. 
INTRODUCTION
Although prognosis for pediatric patients with T-cell acute lymphoblastic leukemia (T-ALL) has improved in recent years with the development of more intensive regimens, B25% of cases develop recurrent disease and post-relapse prognosis remains poor. 1 Furthermore, these improvements have been paralleled by increased toxicity. 2 Factors such as age and tumor burden do not seem to predict for relapse, and risk stratification approaches in current clinical trials are therefore mostly derived from the Berlin-Frankfurt-Munster protocols and based on early response to chemotherapy and minimal residual disease (MRD) evaluation. Identification of additional molecular prognostic markers at diagnosis is therefore needed to discriminate between the lower risk and higher risk patients, so that earlier intervention with more intensive therapy such as hematopoietic stem cell transplantation can be targeted at those at greatest risk of relapse, and dose reduction considered for those at lower risk of relapse. Recent studies have indicated that abnormalities in the NOTCH1 pathway may be suitable candidates. 3, 4 NOTCH1 is a transmembrane receptor that is essential for the commitment of pluripotent progenitors to the T-cell lineage. Ligand binding induces proteolytic cleavage of the receptor, liberating the intracellular portion, which translocates to the nucleus and activates multiple downstream signaling targets. 5, 6 Activating NOTCH1 mutations have been reported in over 50% of pediatric T-ALL patients. [7] [8] [9] [10] [11] [12] Mutations predominantly cluster in the extracellular N-and C-terminal heterodimerization (HD) domains, resulting in ligand hypersensitivity or ligand-independent NOTCH1 activation, 13 and the C-terminal PEST domain where protein truncation removes the target sites for proteolytic cleavage by the E3 ubiquitin ligase, FBXW7, thereby increasing the half-life of intracellular NOTCH1. 7, 14 Less frequent mutations have also been reported in the transcriptional activation domain (TAD), juxtamembrane (JME) domain and Lin-12/Notch repeats (LNR). 7, 15, 16 Approximately 20% of patients have double mutations in both the HD and PEST domains, usually in cis, which lead to synergistic NOTCH1 activation. 7, 17 Inactivating mutations of the FBXW7 gene have also been reported in 8-30% of pediatric T-ALL patients, generally in arginine residues of the WD40 domains. 8, [10] [11] [12] [18] [19] [20] Mutants are unable to bind to the NOTCH1 PEST domain, stabilizing intracellular NOTCH1 in the nucleus, and are thought to mimic NOTCH1 PEST mutations. 21 Mutations in the NOTCH1 PEST domain and FBXW7 in the same patient are infrequent, and a mouse model of radiation-induced T-cell acute lymphoblastic lymphomas has shown that reduced Fbxw7 activity precludes the requirement for Notch1 PEST domain mutations for tumor development. 22 However, co-incident NOTCH1 HD domain and FBXW7 mutations do occur and, as with NOTCH1 HD and PEST domain mutations, act in synergy. 19, 21, 23 Several studies investigating the prognostic significance of NOTCH1 and FBXW7 mutations in pediatric T-ALL have been published. Most agree that the presence of a NOTCH1 mutation is associated with a favorable early response to treatment. 8, 10, 20 However, they do not agree as to whether this transcends into improved long-term survival. Some have reported the association of a NOTCH1 mutation with improved outcome, 11, 20 others that NOTCH1/FBXW7 mutations had no significant effect on prognosis. 8, 10, 12, 24 Although these studies have investigated the impact according to the presence of individual gene mutations or the combined NOTCH1-and FBXW7-mutated group, we reasoned that the latter should be considered jointly with the double NOTCH1-mutated group as they both lead to synergistic NOTCH1 activation and are predicted to be functionally equivalent. We have therefore screened samples from a cohort of pediatric , to determine whether this information can be used to refine risk stratification. The MRC UKALL 2003 trial is registered at http://www.controlled-trials.com under ISRCTN07355119. Details of the trial protocol have been published elsewhere 25 and are outlined in Supplementary Figure S1A . At trial entry, induction therapy was allocated according to the National Cancer Institute (NCI) risk score. Patients with low-risk disease (age 1-10 years and white blood cell count (WBC) o50 Â 10 9 /L) were allocated to a 3-drug induction regimen with vincristine, dexamethasone and asparaginase (regimen A); high-risk patients (age 410 years and/or WBC 450 Â 10 9 /L) were allocated to receive additional daunorubicin (regimen B). Patients who had a morphological slow early response (SER, defined as 425% bone marrow blasts at day 8 or 15 for high-and low-risk patients, respectively), and o16 years of age were then assigned to 'augmented Berlin-Frankfurt-Munster' therapy (regimen C) and received additional asparaginase during the consolidation and delayed intensification phases. At day 29, patients not in morphological remission but with o25% blasts were also reallocated to regimen C. If resistant disease was present (425% blasts), then patients were taken off protocol. MRD was assessed in those with a rapid early response in morphological remission at day 29 using quantitative PCR analysis of leukemia clone-specific rearranged T-cell receptor g and d genes as previously described. 26 If MRD of more than one leukemic cell in 1000 cells (410
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) was present then they were classed as MRD positive and were then randomized to either remain on their assigned regimen (A or B) or to be reallocated to regimen C. Of the 162 patients included in this study, 14 patients were treated on regimen A, 92 on B and 56 on C (Supplementary Figure S1B ).
NOTCH1 and FBXW7 screening
Mutation screening of genomic DNA was carried out by heteroduplex analysis on the WAVE DNA Fragment Analysis System (Transgenomic, Glasgow, UK) of PCR amplicons covering the NOTCH1 LNR-B, HD-N, HD-C, JME, TAD and PEST domains (exons 25-28 and 34) and the FBXW7 WD40 domains (exons [8] [9] [10] [11] [12] . Primer sequences and analysis conditions are given in Supplementary Tables S1 and S2 . Wherever possible, PCR products were obtained using the proof-reading enzyme Optimase (Transgenomic) according to manufacturers' instructions in 20 ml reactions containing B40 ng genomic DNA, 1 Â manufacturer's buffer, 200 mM dNTPs, 10 pmol of each primer and 1 unit of Optimase Polymerase. Due to a high GC content of the HD-C, TAD and JME domains, 1 mol/L betaine was also included in the reaction mix for these amplicons. For the NOTCH1 HD-N, PEST and LNR-B domains, where adequate PCR products could not be obtained using Optimase, the non proof-reading enzyme BIOTAQ DNA Polymerase (BIOLINE, London, UK) was used in 20 ml reactions containing B40 ng genomic DNA, 1 Â manufacturer's buffer, 1.5 mM MgCl 2 , 200 mM dNTPs, 10 pmol of each primer and 0.5 units of BIOTAQ DNA Polymerase. For all amplicons, DNA was amplified by 35 cycles of PCR at the appropriate annealing temperatures. PCR products were denatured, cooled slowly to enable the formation of heteroduplexes and then analyzed on the WAVE DNA Fragment Analysis System (Transgenomic) at optimal melting temperatures calculated using Transgenomic Navigator software (Supplementary Tables S1 and S2 ).
All samples with abnormal WAVE chromatograms were sequenced using fresh PCR products except for the NOTCH1 HD-C domain, where a common synonymous single-nucleotide polymorphism (SNP, C5094T, rs10521, listed allele frequency 0.43 in the dbSNP database; http://www.ncbi.nlm.nih.gov/ projects/SNP/) gave a characteristic chromatogram. All samples with an abnormal WAVE chromatogram for exon 27 were therefore screened by PCR using a mismatch primer that introduces a restriction enzyme digestion site to discriminate between the alleles. A 187 base pair (bp) product was generated using the BIOTAQ DNA Polymerase reaction and cycling conditions for exon 27 with primer 27R and primer SNP-F (Supplementary Table S1 ). Products were digested with BsaA1 (New England Biolabs (UK) Ltd, Hitchin, UK) for 3 h at 37 1C, which gave bands of 158 þ 29 bp for C alleles and a single uncut band of 187 bp for T alleles. Samples identified as containing this polymorphism and with the characteristic WAVE chromatogram for this substitution were scored as WT. All other samples with abnormal exon 27 WAVE chromatograms were sequenced.
Statistical analysis
Outcome was analyzed according to overall survival (OS), defined as the time to death, event-free survival (EFS) which was the time to relapse, secondary tumor or death, and relapse (RR) which was the time to relapse for those that achieved remission, censoring at death in remission. Kaplan-Meier curves were used to assess survival, and differences between groups were compared using the log-rank test. Multivariate analyses were modeled using logistic or Cox regression. All P-values quoted are twosided. The decision to divide the patients according to the three defined genotype groups was made before the analysis.
RESULTS
NOTCH1 mutation analysis
Overall, 119 mutations were detected in the NOTCH1 gene in 101 (62%) of the 162 patients analyzed (NOTCH1 MUT ), 70 (59% of all mutations) in the HD-N and 17 (14%) in the HD-C domain, either missense mutations (47 of 87, 54%) or short in-frame insertions, deletions or indels (40 of 87, 46%) ( Figure 1a) . A total of 25 mutations (21%) were found in the PEST domain, including 21 (84%) insertions, deletions or indels causing a frameshift and two (8%) non-sense mutations (Q2406X, S2487X), all predicted to result in a C-terminally truncated protein, and two missense mutations (F2510L, P2459T). Two non-sense mutations (2%) were detected in the TAD (Q2392X, Q2395X), which also result in C-terminal protein truncation. Four mutations (3%) were found in the JME domain, all large in-frame insertions of 24 bp or more. One missense mutation, C1528R, was found in the LNR-B domain.
Of the 101 NOTCH1 MUT patients, 84 (83%) had a single mutation (NOTCH1 Single ) and 17 (17%) had more than one NOTCH1 mutation, herein denoted as NOTCH1 Double . Of the latter, 14 (82%) were mutated in both the HD (either HD-N or HD-C) and PEST domains, one of which also had an LNR-B mutation, NOTCH1/FBXW7 mutations in pediatric T-ALL S Jenkinson et al two harbored mutations in both the HD-N and HD-C subunits, and one in both the PEST and TAD domains.
FBXW7 mutation analysis For the FBXW7 gene, 31 mutations were detected in 29 patients (18%, FBXW7 MUT ). All were missense mutations, 21 (68%) in exon 9 (20 affecting R465 and 1 R441Q), 8 (26%) in exon 10 (5 R479Q, 2 R505C and 1 G517V) and 2 in exon 12 (R689W) (Figure 1b) . Of note, all mutations except one, G517V, disrupted the conserved arginine residues in the WD40 domains of the gene.
Considering the mutational status of both the NOTCH1 and FBXW7 genes together for all 162 patients, 57 (35%) patients were WT for both genes, 76 (47%) were NOTCH1
MUT only, of which 62 (38% of all cases) were NOTCH1
Single and 14 (9%) were NOTCH1 Double , 4 patients (3%) were FBXW7 MUT only, and 25 (15%) had a mutation in both the NOTCH1 and FBXW7 genes ( Table 1 ). The latter all had a NOTCH1 HD domain mutation coupled with the FBXW7 mutation; two patients also had a mutation in the NOTCH1 PEST domain. There was a positive association between a NOTCH1 HD domain mutation and an FBXW7 mutation, 23 of 71 (32%) patients with NOTCH1 HD-only mutations were FBXW7
MUT versus 6 of 91 (7%) other patients (P ¼ 0.0003). Conversely, cases with a NOTCH1 PEST domain mutation were less likely to have an FBXW7 mutation, 24 of 133 (18%) FBXW7
WT patients had a NOTCH1 PEST domain mutation versus 2 of 29 (6%) FBXW7
MUT patients, but this did not reach statistical significance (P ¼ 0.19).
Characteristics of T-ALL patients according to genotype
Characteristics of the patients studied are given in Table 2 . Compared with the 226 T-ALL patients treated on the trial who did not have molecular data, there were no significant differences in sex, WBC, NCI risk group or central nervous system (CNS) disease at diagnosis, but the patients studied were slightly younger (P ¼ 0.005) (Supplementary Table S3 ).
There was no significant difference in sex, WBC, age group, CNS disease or NCI risk group between the three combined genotype groups, excluding the four patients with FBXW7 mutations alone, nor in cytogenetic characteristics as defined in Supplementary information (Table 2 ).
Prognostic relevance of NOTCH1 and FBXW7 mutations Response to treatment. The presence of either a NOTCH1 or FBXW7 mutation was associated with a lower incidence of SER, but the difference was of borderline significance, SER in 21% NOTCH1
MUT versus 34% NOTCH1 WT patients (P ¼ 0.06) and 14% FBXW7 MUT versus 29% FBXW7 WT patients (P ¼ 0.1) ( Table 3 ). For the three combined genotype groups, the difference was similarly borderline significant, SER in 33% NOTCH1
WT FBXW7
WT , 23% NOTCH1
Single FBXW7 WT and 18% NOTCH1 ± FBXW7 Double patients (P for trend across all groups ¼ 0.08).
The MRD status at day 29 post-diagnosis was available for 151 of the 162 patients. Evaluation for individual genes indicated that NOTCH1
MUT patients were more likely to be MRD negative than NOTCH1
WT patients (59% versus 39%, P ¼ 0.02), whereas FBXW7 mutational status alone had no significant effect (MRD negative in 58% FBXW7
MUT versus 50% FBXW7 WT , P ¼ 0.4) ( 
Abbreviations: HD, heterodimerization domain; JME, juxtamembrane domain; LNR-B, Lin12/Notch repeats; MUT, mutant; TAD, transcriptional activation domain; WT, wild-type.
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favorable outcome in multivariate analysis adjusted for age and WBC as continuous variables (P ¼ 0.0003).
Patient outcome. Outcome data were available for all 162 patients. EFS at 5 years was not significantly different from the 226 excluded patients without molecular data (84% versus 80%, Table S3 ). Median follow-up for the cohort studied was 4.5 years (range 2.3-7.8).
There was no significant difference between NOTCH1 MUT and NOTCH1
WT patients in RR and EFS at 5 years, 11% versus 16% (log-rank P ¼ 0.4) and 87% versus 80% (P ¼ 0.1) respectively, although NOTCH1
MUT patients did show a trend to improved OS (93% versus 83%, P ¼ 0.06) (Supplementary Figures S2A-C) . Outcome for FBXW7
MUT patients was generally better than FBXW7
WT patients, RR 4% versus 15%, respectively (P ¼ 0.08), EFS 93% versus 82% (P ¼ 0.1), and OS 100% versus 87% (P ¼ 0.02) (Supplementary Figures S2D-F 
FBXW7
WT and NOTCH1 ± FBXW7 Double patients, respectively (P for trend ¼ 0.1), and significantly improved EFS (78, 84, and 92%; P ¼ 0.04) and OS (82, 88 and 100%; P ¼ 0.005) (Figures 2a and c ; Table 3 ). This significantly better OS was independent of age and WBC (P ¼ 0.004). Many of the 39 NOTCH1 ± FBXW7 Double patients had characteristics associated with high-risk disease, 20 (51%) were 10 years or older, 25 (64%) had a presenting WBC 450 Â 10 9 /L, with 34 (87%) having NCI high-risk disease (Table 2) . Furthermore, six (15%) of this group, all NCI high risk, had an SER and 12 (31%) had high-level MRD at day 29. Nevertheless, despite the presence of these poor risk factors, only 2 of the 39 relapsed and both remain alive, 1 had a cord blood transplant, the other was transferred to the EURO-LB 02 protocol. e Details of cytogenetics and genetic subgroups are given in Supplementary Information.
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In other studies, the impact of a NOTCH1 mutation has differed according to risk group. In the Berlin-Frankfurt-Munster study, the favorable outcome associated with NOTCH1 mutations was restricted to those patients with a good response to induction therapy, with no difference in the high-risk group of patients who had either an SER or were MRD positive. 19 The EORTC study reported a very poor prognosis in NOTCH1
MUT high-risk patients, and a high number of CNS relapses in NOTCH1 MUT patients. 10 To examine this in our cohort, outcome was analyzed according to genotype in a high-risk group of 85 patients with either an SER or MRD positive and a low-risk group of 73 patients with a rapid early response and either MRD negative or MRD status unknown. OS for the NOTCH1±FBXW7 Double patients did not differ according to risk group, all patients were still alive (Figures 3a and b) , and there NOTCH1/FBXW7 mutations in pediatric T-ALL S Jenkinson et al was some evidence that the favorable impact of the genotype was greater in the high-risk than in the low-risk group (P for heterogeneity ¼ 0.05). This difference was not seen for RR or EFS. Of the 14 high-risk double-mutated patients, none had received a transplant, 1 was treated on regimen A (low/standard risk), 5 on regimen B (intermediate risk) and 8 on regimen C (high risk). There was no difference in the incidence of CNS relapse across the three genotype groups (P ¼ 0.2); the highest incidence (10%) was in the NOTCH1 Single FBXW7 WT group (Table 3) .
DISCUSSION
T-ALL is a highly heterogeneous disorder with a dismal prospect for salvage in patients that relapse. Knowledge of clearly defined prognostic markers at diagnosis could therefore help to refine current risk stratification strategies that are based on response to therapy and inform clinical decisions, in particular which patients should proceed to allogeneic stem cell transplantation. An early report on the impact of NOTCH1 mutations in pediatric patients indicated that they might be a suitable candidate prognostic marker, with a favorable effect of NOTCH1 mutations reported for both early response to therapy and long-term outcome, 9 but although the same group have confirmed these results in a larger cohort, 20 other studies have not been able to replicate this benefit. 8, 10, 12, 24 The impact of FBXW7 mutations was more consistent, with mutations associated with a favorable early response to treatment but not long-term outcome. The variable effects have been attributed to differences in treatment in the various trials, 27 but differences in the combination of mutations may also be a significant factor. In our study, the incidence of NOTCH1 and FBXW7 mutations was similar to that reported in other pediatric cohorts, 8, 10, 11, 20 These results contrast with the lack of prognostic significance reported by others 8, 12, 24 and, in particular, with the absence of impact or very poor outcome reported for high-risk NOTCH1 MUT patients. 10, 20 This may reflect the different genotype groups used in our study; when outcome for these patients was stratified according to individual gene mutant status, only OS with/without an FBXW7 mutation was significantly different. In addition, there was no evidence in our patients that lack of cranial irradiation leading to increased CNS relapse was a contributory factor to outcome, as has been suggested by others. 20 Current whole genome analyses have demonstrated that the genomic landscape for individual T-ALL patients is generally highly hetereogeneous, [28] [29] [30] and it is possible that our NOTCH1± FBXW7 Double patients have other collaborating mutations that are associated with better outcome or lack prognostically adverse factors. Recent evidence has also indicated that significance of the mutation is context dependent, with reports of activating NOTCH1 mutations, frequently in the TAD and PEST domains, in both chronic lymphocytic leukemia and mantle cell lymphoma being associated with aggressive disease and poor OS. [31] [32] [33] Nevertheless, determining the contribution of coincident mutations to outcome in T-ALL is likely to be challenging due to the relative rarity of the disease.
Our results suggest that knowledge of NOTCH1/FBXW7 genotype may have a role in refining risk stratification by adding valuable information to morphological and MRD studies. Screening could be limited to patients who are classified as high-risk post-induction therapy, with NOTCH1±FBXW7 Double patients not considered for further intensification of therapy in first remission, including allogeneic stem cell transplantation. NOTCH1/FBXW7 mutations in pediatric T-ALL S Jenkinson et al trial MRD co-ordinator; AVM provided data; SJ, DCL and REG wrote the manuscript with contributions from other authors as appropriate.
